LCL161 monotherapy is under assessment in a phase II trial in patients with different forms of myelofibrosis, as well as in various oncology indications in combination with other drugs such as topotecan, cyclophosphamide, the anti-PD-1 antibody PDR001, or the anti-IL17 antibody CJM112 (NCT02649673, NCT01955434, NCT03111992, NCT02098161, NCT02890069). The gene discussed is IL17A; the disease is myelofibrosis.